Clinical trials: Atopy
Atopic Dermatitis
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD)…
- Trial name
- AD Up (NCT03568318)
- Testing
- Upadacitinib, Topical corticosteroids (TCS)
- Where
- 193 sites in United States, Australia and 22 more
- Volunteers
- 1,533 people
- Sponsor
- AbbVie
Dermatitis, Atopic
Efficacy and Safety Study of Advantan for Maintenance Treatment of Atopic Dermatitis
Purpose of the study: One bothering feature of atopic dermatitis is its relapsing nature. Hence, it is worthwhile to test modes how to efficiently prevent relapses or at least increase the time until the disease recurs.
- Trial name
- NCT00185510
- Testing
- Methylprednisolone Aceponate (Advantan, BAY86-4862)
- Volunteers
- 250 people
- Sponsor
- LEO Pharma
Diarrhea, Atopic Dermatitis
Cesarean Section Study
Effect, tolerance and safety of a supplementation with a probiotic on the risk of gastrointestinal infections, on growth, and on gut microbiota in healthy newborn term infants born by Cesarean section.
- Trial name
- NCT01992497
- Testing
- Probiotic
- Where
- Germany
- Volunteers
- 721 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Vernal Keratoconjunctivitis, Atopic Keratoconjunctivitis
Dermatologic Tacrolimus Ointment on Eyelids in the Treatment of Refractory Vernal Keratoconjunctivitis and Atopic Keratoconjunctivitis
To evaluate the therapeutic effects of dermatologic tacrolimus ointment on eyelids to treat refractory vernal keratoconjunctivitis and atopic keratoconjunctivitis.
- Conditions
- Vernal Keratoconjunctivitis, Atopic Keratoconjunctivitis, Tacrolimus
- Trial name
- NCT03557203
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- National Taiwan University Hospital
Atopic Dermatitis
A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD)
This is a A multicenter, open label, phase II clinical study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics(PD), and preliminary efficacy of AK120 in adolescents with moderate-to-severe atopic dermatitis
- Trial name
- NCT06756126
- Testing
- AK120
- Where
- 6 sites in China
- Volunteers
- 24 people
- Sponsor
- Akeso
Atopic Dermatitis (Eczema)
Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema
This is a research study where all subjects will receive study medication to understand how the body processes the study medication, and to determine the PK, safety and efficacy of ARQ-151 cream 0.15% or 0.05% in adolescent and…
- Trial name
- NCT04156191
- Testing
- ARQ-151 cream 0.15%, ARQ-151 cream 0.05%
- Where
- 10 sites in United States
- Volunteers
- 101 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Eczema, Atopic Dermatitis
Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis
This is an investigator-blinded, bilateral comparison study in 30 subjects with atopic dermatitis. It is designed to assess and compare the efficacy of Elidel® (pimecrolimus) cream 1% and Hylatopic™ Plus Emollient Foam™ in…
- Trial name
- NCT01202149
- Testing
- Elidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Frankel, Amylynne, M.D.
Dermatitis, Atopic, Eczema
Behavioral Self-Help Intervention for Pediatric Atopic Dermatitis and Eczema Patients
Patients with atopic dermatitis and eczema often struggle with habitual scratching that is not well-controlled even with optimal medical therapy.
- Trial name
- NCT02713035
- Testing
- Self help intervention
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Mississippi Medical Center
Dermatitis Atopic
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
This is a single group, 1-arm, long-term safety study for treatment of participants with moderate to severe atopic dermatitis (AD).
- Trial name
- ATLANTIS (NCT05769777)
- Testing
- Amlitelimab
- Where
- 174 sites in United States, Argentina and 23 more
- Volunteers
- 999 people
- Sponsor
- Sanofi
Atopic Skin, Children
A Probiotic That Reduces Atopic Skin
To assess the efficacy and safety of the use of probiotics as food supplements in reducing the SCORAD index in children with atopic skin compared with placebo.
- Trial name
- NCT05989295
- Testing
- probiotic LRa05
- Where
- 2 sites in Spain
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Atopic Dermatitis
Equivalence of the Response to Vaccination of Tacrolimus Ointment to a Steroid Ointment Regimen in Children With Atopic Dermatitis
Seven-month study in pediatric patients (2-11 years) with moderate to severe AD who were considered to benefit from vaccination to prevent invasive disease caused by Neisseria meningitides serogroup C.
- Trial name
- NCT00801957
- Testing
- tacrolimus ointment 0.03%, hydrocortisone acetate ointment 1%, hydrocortisone butyrate ointment 0.1%
- Where
- 36 sites in Australia, Belgium and 6 more
- Volunteers
- 260 people
- Sponsor
- Astellas Pharma Inc
Mild to Moderate Atopic Dermatitis
Observational Study to Evaluate Use of Elidel® in South and East Asian Pediatric Patients With Atopic Dermatitis.
Elidel® is indicated for the short-term treatment and long-term management of signs and symptoms of atopic dermatitis (AD) in infants (3 to 23 months), children (2 to 11 years), adolescents (12 to 17 years), and adults.
- Trial name
- Elidel-SEA (NCT06052995)
- Testing
- Elidel 1% Topical Cream
- Where
- 9 sites in Malaysia, Taiwan and 1 more
- Volunteers
- 130 people
- Sponsor
- BGP Products Operations GmbH, a Viatris company
Dermatitis, Atopic
Place of Flixovate® in the Treatment Pathway and Its Conditions of Use in Infants Aged From 3 to 12 Months Between 2010 and 2012 by French GPs and Private Paediatricians
this study has been request by french health authorities to evaluate the use of flixovate in infants and its place in the treatment pathway.
- Trial name
- flixovate HAS (NCT01920464)
- Volunteers
- 160 people
- Sponsor
- GlaxoSmithKline
Dermatitis Atopic
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 years and older diagnosed with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ESTUARY (NCT06407934)
- Testing
- Amlitelimab
- Where
- 324 sites in United States, Argentina and 25 more
- Volunteers
- 1,541 people
- Sponsor
- Sanofi
Cow's Milk Allergy, Atopic Disease
Effect Of Lactobacillus GG on Atopic March
Food allergy (FA), defined as an adverse immune response to food allergens, is among the most frequent allergic disorders in childhood and it has recognized as a major paediatric health problem due to the severity of the…
- Trial name
- NCT01891916
- Testing
- Extensively hydrolyzed casein formula + LGG
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Federico II University
Atopic Dermatitis
Optimization of Cyclosporin in Atopic Dermatitis Through Multiomic Predictive Models of Treatment Response
This is a low-intervention phase IV trial. The main objective is to optimize the treatment of patients with moderate-severe atopic dermatitis who require systemic treatment.
- Trial name
- DermAtOmics (NCT05692843)
- Testing
- Cyclosporin A, Follow-up of Cyclospoin treatment already started
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Atopic Dermatitis
Cetaphil Restoraderm Effect on Young Children With Atopic Dermatitis
The purpose of this study is to evaluate the effect of Cetaphil® Restoraderm® skin restoring moisturizer in reducing the signs and symptoms of very dry atopic skin in young children.
- Trial name
- NCT02589392
- Testing
- Cetaphil® Restoraderm® moisturizer + Cetaphil® Restoraderm® body wash, Cetaphil® Restoraderm® body wash
- Where
- 8 sites in China, Philippines
- Volunteers
- 120 people
- Sponsor
- Galderma R&D
Dermatitis, Atopic
A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab
The purpose of this study is to assess the effect of nemolizumab (CD14152) on humoral immune responses to tetanus and meningococcal vaccination in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT04365387
- Testing
- Nemolizumab
- Where
- 64 sites in United States
- Volunteers
- 242 people
- Sponsor
- Galderma R&D
Atopic Dermatitis
Comparative Analysis of Filmed Sequences for the Assessment of Discomfort in Atopic Dermatitis of Infants Under 6 Months of Age
Atopic dermatitis (AD) is an frequent chronic and itchy inflammatory dermatitis which concern about 20% of pediatric population with a revelation usually toward 3-6 months of live.
- Trial name
- PRURINEO (NCT03684343)
- Testing
- Filmed consultation with a dermatologist
- Where
- France
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
Non IgE Mediated Food Allergy, Food Protein-Induced Enteropathy
Non-Immunoglobulin E-mediated Food Allergies in Children
Non-IgE-mediated gastrointestinal food allergies (non-IgE-GIFA) are an evolving web of clinical conditions characterized by subacute and/or chronic symptoms and include food protein-induced enterocolitis syndrome (FPIES), food…
- Conditions
- Non IgE Mediated Food Allergy, Food Protein-Induced Enteropathy, Food Protein-Induced Proctocolitis, Food Protein-Induced Enterocolitis Syndrome
- Trial name
- NIGEFA (NCT04462978)
- Testing
- Non IgE-mediated food allergy
- Where
- Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Federico II University